EUVIMEDEUVIMED entdecken
Open Access

Functional Status and Quality of Life in Light-Chain Amyloidosis

Olivier F Clerc, Shilpa Vijayakumar, Sarah A M Cuddy, Giada Bianchi, Jocelyn Canseco Neri, Alexandra Taylor, Dominik C Benz, Yesh Datar, Marie Foley Kijewski, Andrew J Yee, Frederick L Ruberg, Ronglih Liao und 3 weitere

JACC: Heart Failure · 2024

DOI: 10.1016/j.jchf.2024.07.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Heart Failure, 2024. Verfasst von Olivier F Clerc und 14 weiteren Autor:innen. Beteiligte Einrichtung: Cardiac Amyloidosis Program, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA; Division of N…. Hauptthemen laut MEDLINE: Quality of Life, Immunoglobulin Light-chain Amyloidosis, Functional Status, Heart Failure. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, American Heart Association-American Stroke Association, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In light-chain (AL) amyloidosis, whether functional status and heart failure-related quality of life (HF-QOL) correlate with cardiomyopathy severity, improve with therapy, and are associated with major adverse cardiac events (MACE) beyond validated scores is not well-known. OBJECTIVES: The authors aimed to: 1) correlate functional status and HF-QOL with cardiomyopathy severity; 2) analyze their longitudinal changes; and 3) assess their independent associations with MACE. METHODS: This study included 106 participants with AL amyloidosis, with 81% having AL cardiomyopathy. Functional status was evaluated using the NYHA functional class, the Karnofsky scale, and the 6-minute walk distance (6MWD), and HF-QOL using the MLWHFQ (Minnesota Living with Heart Failure Questionnaire). Cardiomyopathy severity was assessed by cardiac 18F-florbetapir positron emission tomography/computed tomography, cardiac magnetic resonance, echocardiography, and serum cardiac biomarkers. MACE were defined as all-cause death, heart failure hospitalization, or cardiac transplantation. RESULTS: NYHA functional class, Karnofsky scale, 6MWD, and MLWHFQ were impaired substantially in participants with recently diagnosed AL cardiomyopathy (P < 0.001), and correlated with all markers of cardiomyopathy severity (P ≤ 0.010). NYHA functional class, 6MWD, and MLWHFQ improved at 12 months in participants with cardiomyopathy (P ≤ 0.013). All measures of functional status and HF-QOL were associated with MACE (P ≤ 0.017), independent of Mayo stage for 6MWD and MLWHFQ (P ≤ 0.006). CONCLUSIONS: Functional status and HF-QOL were associated with AL cardiomyopathy severity, improved on therapy within 12 months, and were associated with MACE, independently of Mayo stage for 6MWD and MLWHFQ. They may be validated further in addition to prognostic scores and as surrogate outcomes for future studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeImmunoglobulin Light-chain AmyloidosisFunctional StatusHeart FailureHumansFemaleMaleMiddle AgedAgedCardiomyopathiesSeverity of Illness IndexEchocardiographyWalk TestPositron Emission Tomography Computed TomographyLongitudinal Studies

Stichwörter der Autor:innen

Light-chain (AL) amyloidosiscardiomyopathyfunctional statusheart failure–related quality of lifelongitudinal changesmajor adverse cardiac outcomes

Autor:innen und Institutionen

  • Cardiac Amyloidosis Program, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA; Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigha…
  • Cardiac Amyloidosis Program, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Bosto…
  • Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Section of Cardiovascular Medicine, Department of Medicine, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA; Amyloidosis Center, Boston University Chobania…
  • Amyloidosis Program, Stanford University, Stanford, California, USA.

Förderung

  • NHLBI NIH HHS
  • American Heart Association-American Stroke Association
  • NIH
  • American Heart Association Inc

Zitieren

APA

Clerc, O. F., Vijayakumar, S., Cuddy, S. A. M., Bianchi, G., Canseco Neri, J., Taylor, A., Benz, D. C., Datar, Y., Kijewski, M. F., Yee, A. J., Ruberg, F. L., Liao, R., Falk, R. H., Sanchorawala, V., & Dorbala, S. (2024). Functional Status and Quality of Life in Light-Chain Amyloidosis. JACC: Heart Failure. https://doi.org/10.1016/j.jchf.2024.07.007

Vancouver

Clerc OF, Vijayakumar S, Cuddy SAM, Bianchi G, Canseco Neri J, Taylor A, et al. Functional Status and Quality of Life in Light-Chain Amyloidosis. JACC: Heart Failure. 2024. doi:10.1016/j.jchf.2024.07.007

BibTeX
@article{Clerc2024,
  author = {Clerc, Olivier F and Vijayakumar, Shilpa and Cuddy, Sarah A M and Bianchi, Giada and Canseco Neri, Jocelyn and Taylor, Alexandra and Benz, Dominik C and Datar, Yesh and Kijewski, Marie Foley and Yee, Andrew J and Ruberg, Frederick L and Liao, Ronglih and Falk, Rodney H and Sanchorawala, Vaishali and Dorbala, Sharmila},
  title = {Functional Status and Quality of Life in Light-Chain Amyloidosis},
  journal = {JACC: Heart Failure},
  year = {2024},
  doi = {10.1016/j.jchf.2024.07.007}
}
Kostenlos starten →